Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Altcoin FET Enters a Correction Phase After Latest Rejection, Analysts Reveal What Prices to Watch

Altcoin FET Enters a Correction Phase After Latest Rejection, Analysts Reveal What Prices to Watch

CryptonewslandCryptonewsland2026/10/08 14:48
  • Altcoin FET enters a correction phase after latest rejection.
  • Analysts reveal what prices to watch next.
  • Will the altseason peak phase arrive soon and take FET to new ATHs. 

The crypto market enters a short correction phase, which analysts believe will conclude over 2-3 weeks. Already, the price of Bitcoin and Ethereum have dipped from $87,000 to $82,000 and $2,700 to $2,500, respectively. This correction is playing out differently for different altcoins. Specifically, altcoin FET enters a correction phase after the latest rejection, leading to analysts revealing what prices to watch for next.

Altcoin FET Enters a Correction Phase After Latest Rejection 

According to CoinMarketCap analytics, the price of FET is currently trading at $0.23, showing that the asset is down by 1.27% in the last 24 hours and down by almost 2.5% in the last 7 days. However, over the last 30 days, the price of FET is up by over 23%. The altcoin will need to see a pump of over 93% to reclaim its previous ATH set 3 years ago at $3.47. 

As we can see from the post above, this post goes on to explain why the price of FET has been dropping over the last 7 days. To highlight, the expert confirms that the price of FET is correcting after rejection near $0.265 – $0.270, but the broader structure still shows higher lows. Presently, the price of FET is trading around $0.233 after testing the latest support zone at $0.221 – $0.225. 

Analysts Reveal What Prices to Watch

What’s more, the post confirms that spot volumes have remained strong throughout the move, supporting the broader recovery. Thus, buyers now need to defend this support zone and reclaim $0.240. A breakout followed by a retest that holds could trigger a move towards the $0.250 – $0.257 price range, with the $0.265 – $0.270 price range expected after. The key to avoid is a break below the $0.220 price level. 

Adding to the conversation, the analyst in the post above highlights how the price of FET is far from its previous ATH. At the moment, the analyst believes that FET is attempting to recover from its weekly base. Thus, he claims that the first real test is reclaiming the $0.3 – $0.45 price range, and holding it through a retest. 

The post then goes on to conclude that in a sustained bullish reversal, he is watching $1, $2.10, and then the historical high near $3.50 for FET to surge to. That final level sits roughly 1,336% above the chart’s $0.2437 price. It requires a full trend recovery, not just a bounce. A weekly close below $0.12 invalidates this recovery scenario. 

News Image 0
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data

On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)

路透社•2026/10/08 18:26